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We analyzed our historic patient database at North Shore 
University Hospital and determined both the overall frequency 
of anti-Jsa and the frequency at which it was detected in 
combination with other alloantibodies to red blood cell (RBC) 
antigens. Screening cells used currently are negative for Jsa. 
Our data suggest that anti-Jsa would not be detected in 30 to 40 
percent of patients in which it is the sole antibody present. Since 
1996 the antibody was only detected when other antibodies were 
found in the screening process. We are exposing 1.7 percent of 
our patients (90 patients/year) to Jsa. The clinical significance of 
anti-Jsa is apparent with previous literature, and our conclusion 
is that additional studies should be performed to determine 
whether Jsa should be included in current antibody screening 
cells. Immunohematology 2011;27:104–106.
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Jsa is generally considered a low-prevalence blood group 
antigen. Jsa was first identified in 1958. At that time, the red 
cell antigen was named Sutter after the patient whose serum 
demonstrated the antibody. In 1965, Jsa and Jsb were identified 
and categorized under the Kell blood group system. The Kell 
blood group system is the most immunogenic after the ABO 
and Rh blood group systems.1
Less than 0.01 percent of Caucasians are found to be 
positive for Jsa. However, 19.5 percent of African Americans 
are positive for Jsa. Issitt1 has reported that in 1000 random 
black donors, 7 were Js(a+b–), 152 were Js(a+b+), and 842 
were Js(a–b+). Anti-Jsa is seen infrequently because it has 
been hypothesized that fewer donors are positive for Jsa, 
considering that fewer blacks donate blood.1 In the New York 
City area, approximately 8 percent of the donor population 
is African American, as per the New York Blood Center’s 
(NYBC’s) statistics.2 At North Shore University Hospital 
(NSUH) we obtain close to 97 percent of our blood from 
the NYBC. At approximately 26,000 RBC transfusions per 
year, 1.7 percent of our patients are transfused with RBCs 
positive for the Jsa antigen. The NYBC has also reported that 
the incidence of detecting anti-Jsa in their antibody workups 
has increased from 14 (1980–1984) to 86 (2005–2009) in an 
increasingly diverse population of blood donors.3
Most examples of anti-Jsa occur when the patient has 
had a RBC transfusion or pregnancy, but the antibody has 
also been discovered without an allogeneic RBC exposure. 
The antibody has been demonstrated to cause hemolytic 
transfusion reactions4 and hemolytic disease of the newborn 
(HDN), both mild and severe.5 In the last 15 years, reagent 
RBCs used to screen for blood group antibodies were negative 
for Jsa, minimizing the detection of the antibody in our patient 
population.6,7 Therefore, the antibody would be detected only 
when other antibodies are detected in the screening process. 
The antibody would be mostly detected in Caucasians because 
they have the lowest prevalence of the antigen and are more 
likely to develop anti-Jsa.8,9
The racial distribution of the patients at NSUH who 
displayed anti-Jsa was as follows: 17 Caucasian  (50%); 4 
African American  (12%); 4 Asian (12%); 3 Hispanic (9%); and 
6 unknown or other (17%).
Materials and Methods
We performed a retrospective study of our transfused 
patient population and also of the antibodies identified during 
the same time frame. Using the blood bank’s computer system, 
we generated a general database scan report to identify the 
patients who had been assigned a computer flag or antibody 
alert for anti-Jsa for the period of January 1, 1989, to April 6, 
2010. We reviewed each patient for the following information: 
dates of positive antibody screen results and panel results, 
antibody identification result(s), and race (Table 1).
Results
The total number of patients during the period 1989 to 
the present who had anti-Jsa present in their serum was 34. 
Using this information, we determined the prevalence of the 
antibody when detected with at least one other antibody and 
when solely detected. Sixty-eight percent of these patients 
had anti-Jsa present in combination with another antibody. 
Thirty-two percent of these patients had anti-Jsa solely 
present. For the period 1989 to 1995, anti-Jsa was found both 
in combination and solely (58% and 42%, respectively). For 
the period 1996 to the present, 100 percent of the examples of 
anti-Jsa were found only in combination with other antibodies 
(Table 2, Fig. 1). We also generated a report for the total 
number of patients transfused within the same period. We 
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found that 0.08 percent of our transfused patients had anti-
Jsa detected in their serum during the period 1989 to 1995 
and only 0.01 percent of our transfused patients had anti-Jsa 
detected in their serum during the period 1996 to the present 
(Table 2).
Our antibody screening methodology during the years 
has been as follows: 1989 to 1994, test tube low-ionic-strength 
saline; 1995 to 2008, gel; and 2009 to present, Galileo Echo 
Instrumentation, Immucor, Norcross, Georgia 30091.
Discussion
Screening cells currently used are negative for Jsa. Based 
on our data, it appears that anti-Jsa would not be detected 
Table 1. Results of anti-Jsa occurrences in our patient population
1st admission
Date of 1st positive  
ABSC/panel ABID result
Date of 2nd positive  
ABSC/panel ABID result
Date of 3rd positive  
ABSC/panel ABID result
1/18/83 1/14/90 Anti-Jsa/anti-P1 n/a n/a n/a n/a
3/11/85 1/25/89 Anti-Jsa/anti-K n/a n/a n/a n/a
8/30/88 2/21/89 Nonspecific 10/4/89 Anti-Jsa n/a n/a
2/2/89 10/16//94 Anti-K 1/20/00 Anti-Jsa 2/28/00 Anti-V
5/3/89 12/8/94 Anti-Jsa 12/12/94 Anti-E n/a n/a
6/5/89 6/5/89 Anti-Jsa n/a n/a n/a n/a
1/6/90 1/23/90 Anti-Jsa n/a n/a n/a n/a
1/8/90 2/6/93 Anti-K 2/6/93 Anti-Jsa/anti-V n/a n/a
9/6/90 10/28/93 Anti-Jsa n/a n/a n/a n/a
12/25/90 2/12/96 Anti-Jsa/anti-K n/a n/a n/a n/a
5/29/91 7/16/91 Anti-Jsa 7/18/91 Anti-E n/a n/a
9/16/91 11/1/91 Anti-C 2/15/95 Anti-Jsa 4/14/95 and 9/6/96 Anti-e/anti-K
10/8/91 10/8/91 Anti-Jsa n/a n/a n/a n/a
2/13/92 6/29/94 Anti-Jsa, anti-Kpa, 
anti-S, anti-K, anti-D
7/20/94 Anti-C 12/7/94 Anti-Fya
4/6/92 4/28/92 Cold 2/5/93 Anti-Jsa 2 n/a
1/23/93 9/12/94 Anti-K/anti-Kpa/anti-E 11/1/94 Anti-c 11/2/94 Anti-Jsa
7/16/93 10/25/93 Nonspecific 10/27/93 Anti-Jsa n/a n/a
9/25/93 10/16/93 Anti-Jsa n/a n/a n/a n/a
10/24/93 1/8/94 Anti-K 10/31/94 Anti-D 11/1/94 and 4/25/95 Anti-Jsa/anti-E/anti-C
10/25/93 10/25/93 Nonspecific 8/5/95 Anti-Jsa/anti-K 9/22/98 Nonspecific
4/24/94 4/24/94 Anti-Leb 11/23/97 Anti-Jsa n/a n/a
5/5/94 5/5/94 Anti-Jsa n/a n/a n/a n/a
11/10/94 11/10/94 Autoanti-I 7/12/97 Anti-Jsa n/a n/a
12/12/94 3/10/95 Anti-Jsa n/a n/a n/a n/a
3/22/95 7/19/95 Anti-Jsa n/a n/a n/a n/a
4/24/95 4/24/95 Nonspecific 6/14/95 Anti-Jsa/anti-E/ 
anti-K
n/a n/a
5/25/95 5/25/95 Anti-Jsa/anti-K n/a n/a n/a n/a
9/26/95 9/27/95 Anti-Jsa n/a n/a n/a n/a
2/10/96 2/11/96 Anti-Jsa/anti-K n/a n/a n/a n/a
2/21/97 2/21/97 Anti-Jsa/anti-D/ 
nonspecific
n/a n/a n/a n/a
4/30/97 5/2/97 Anti-Jsa/cold n/a n/a n/a n/a
6/12/97 6/17/97 Anti-Jsa/anti-K n/a n/a n/a n/a
8/11/97 10/4/97 Anti-Jsa/anti-K n/a n/a n/a n/a
6/8/98 6/9/98 Anti-Fya/anti-E 8/28/01 Anti-M 9/5/01, 12/16/03  
and 6/10/04
Anti-Fyb/anti-K/anti-Jsa
ABSC = antibody screen, ABID = antibody identification, n/a = not applicable
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in 40 percent of patients in which it is the sole antibody 
present. Since 1996 the antibody was only detected when 
other antibodies were found in the screening process. We are 
exposing 1.7 percent of our patients to Jsa. We have seen a 
decrease in the percentage of our patients who display anti-
Jsa, and we are only detecting it when in combination with 
other antibodies. For the period 1989 to 1995, 0.08 percent of 
our patients were identified as having anti-Jsa compared with 
0.01 percent of our patients for the period 1996 to the present. 
Our antibody screening method has also changed during this 
period, and it is unclear whether the method contributed to 
the decrease of identifying the antibody. However, the fact that 
sole examples of anti-Jsa are not being identified suggests that 
the lack of Jsa on the screening cells has also contributed to 
this decline in anti-Jsa being identified.
At this time we have not had any reports of adverse events 
attributable to anti-Jsa missed in a patient’s antibody screen. 
In conclusion, we suggest that because the possibility of a 
significant clinical event exists, more data would be helpful 
regarding the actual rate of exposure and conversion rate.
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1989–present 23 (68%) 11 (32%)
1989–1995 15 (58%) 11 (42%) 30,620 0.08%
1996–present 8 (100%) 0 (0%) 74,773 0.01%
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